Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Goy on the Combination of Biological Therapies in Relapsed MCL

August 3rd 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the combination of biological therapies in the treatment of patients with relapsed mantle cell lymphoma (MCL).

Dr. Kahl on the Potential of CAR T-Cell Therapy in MCL

August 3rd 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of chimeric antigen receptor (CAR) T-cell therapy in mantle cell lymphoma (MCL).

Dr. Goy on the Evolution of Treatment in Mantle Cell Lymphoma

July 26th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolution of treatment in mantle cell lymphoma (MCL).

Dr. Kahl Discusses the Potential of Frontline Ibrutinib in MCL

July 25th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine in St. Louis, Siteman Cancer Center, discusses the potential of frontline ibrutinib (Imbruvica) in the treatment of patients with mantle cell lymphoma.

Maintenance Rituximab Linked to Improved Outcomes in MCL

July 16th 2018

Talal Hilal, MB, BCh, discusses the findings of a meta-analysis of rituximab maintenance for patients with mantle cell lymphoma (MCL), and the approach to maintenance therapy in patients with MCL.

Dr. Hilal Discusses Study of Rituximab Maintenance in MCL

July 13th 2018

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses a study of rituximab (Rituxan) maintenance in patients with mantle cell lymphoma (MCL) after induction chemoimmunotherapy.

MCL Researcher Highlights Future of CAR T-Cell Therapy, Other Approaches

July 12th 2018

Michael Wang, MD, discusses what he hopes to find in the ZUMA-2 trial and his belief that MCL can be cured in his lifetime.

Dr. Eyre Discusses Venetoclax Monotherapy in MCL

July 10th 2018

Toby Eyre, MBChB, MRCP, consultant hematologist at Oxford University Hospitals NHS Foundation Trust, discusses venetoclax (Venclexta) monotherapy in patients with mantle cell lymphoma.

Expert Discusses Venetoclax Potential in MCL

June 22nd 2018

Toby Eyre, MBChB, MRCP, discusses the results of the phase I study with venetoclax in patients with poor-risk relapsed/refractory mantle cell lymphoma.

Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma

June 22nd 2018

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).

Dr. Wang Discusses the ZUMA-2 Trial in Mantle Cell Lymphoma

June 12th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses the ZUMA-2 trial in patients with relapsed/refractory mantle cell lymphoma.

Dr. Hilal Discusses Rituximab Maintenance in Mantle Cell Lymphoma

June 8th 2018

Talal Hilal, MB, BCh, assistant professor of medicine, Mayo Clinic, discusses the meta-analysis of rituximab maintenance for patients with mantle cell lymphoma.

CAR T-Cell Therapy Explored in Mantle Cell Lymphoma

June 7th 2018

The CD19-targeted CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) is currently being investigated in patients with relapsed/refractory MCL in the ongoing ZUMA-2 trial.

Ibrutinib/Buparlisib Reaches Response in Half of NHL Cohort

June 7th 2018

Combining the BTK inhibitor ibrutinib (Imbruvica) with the PI3K inhibitor buparlisib induced an objective response in 18 of 37 patients with relapsed/refractory non-Hodgkin lymphoma.

CDK4 Inhibition With Palbociclib in MCL

May 22nd 2018

Selina Chen-Kiang, PhD, professor of pathology and immunology, Weill Cornell Medicine, discusses CDK4 inhibition with palbociclib (Ibrance) in mantle cell lymphoma.

CDK4/6 Inhibition Shows Early Promise in Mantle Cell Lymphoma

May 18th 2018

Selina Chen-Kiang, PhD, details the research being conducted with CDK4/6 inhibitors in mantle cell lymphoma.

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL

May 9th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Dr. Goy Discusses the Evolution of Treatment for MCL

May 9th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr. Leslie Discusses Advancements in Mantle Cell Lymphoma

April 28th 2018

Lori A. Leslie, MD, lymphoma attending, John Theurer Cancer Center, discusses advancements in mantle cell lymphoma.

CAR T-Cell Therapy Starts to Enter MCL Space

April 23rd 2018

Frederick L. Locke, MD, discusses the ongoing ZUMA-2 trial investigating axi-cel for patients with mantle cell lymphoma.